A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.